COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00837564
Recruitment Status : Unknown
Verified July 2010 by University Hospital Freiburg.
Recruitment status was:  Recruiting
First Posted : February 5, 2009
Last Update Posted : June 30, 2010
University Hospital, Bonn
Information provided by:
University Hospital Freiburg

Brief Summary:
60 patients with chronic major depressive disorder according to DSM-IV will be included into the study. Patients will be randomized to receive an open treatment either with CBASP, a psychotherapy for chronic depression, or pharmacological treatment with Escitalopram for 28 weeks.

Condition or disease Intervention/treatment Phase
Chronic Depression Other: CBASP psychotherapy Drug: Escitalopram Phase 3

Detailed Description:
The psychotherapeutic treatment with CBASP will be conducted in 2 weekly sessions for the first 4 weeks, one per week thereafter until week 9, followed by one session every 2 weeks for 20 more weeks. The starting dose for Escitalopram will be 10 mg/d for one week and will be increased to 20 mg/d after one week. The dosage can be reduced to 10 mg/d after day 7 to improve tolerance. Th MADRS-scale is the primary outcome measure; ratings will be performed by a blinded rater. If there is no improvement (reduction of less than 20% of the MADRS), patients will be crossed over in terms of adding the other treatment at week 8. Study patients will be asked to participate in fMRI, genetic and pharmacological substudies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Differential Responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP)Versus Escitalopram in Chronic Major Depression With and Without Early Trauma
Study Start Date : February 2009
Estimated Primary Completion Date : April 2010
Estimated Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CBASP
CBASP psychotherapy
Other: CBASP psychotherapy
specific psychotherapy for chronic depression

Experimental: Escitalopram
Escitalopram pharmacotherapy and clinical management
Drug: Escitalopram
Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management

Primary Outcome Measures :
  1. Depressive symptomatology after 8 weeks after randomization as measured by the MADRS [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Depressive symptoms and remission 28 weeks after randomization; social, interpersonal and work function 28 weeks after randomization [ Time Frame: 28 weeks after ranomization ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic MDD according to DSM-IV (modification: depressive symptomatology for at least one year), or recurrent MDE (third or greater episode with the immediately preceding episode being no more than 2.5 years before the onset of the present episode)
  • Age 18-65
  • Score of at least 18 on the Montgomery-Asberg-Rating Scale for Depression (MADRS)

Exclusion Criteria:

  • Acute risk for suicide
  • History of psychotic symptoms, bipolar disorder or dementia
  • Severe substance-related abuse or dependence disorder
  • Schizotypal, antisocial or borderline personality disorder
  • Serious medical condition
  • Severe cognitive impairment
  • Absence of a response to previous adequate trial of the study medication/CBASP
  • Hypersensitivity to Escitalopram
  • Treatment with a MAO-inhibitor within 1 week before the initiation of study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00837564

Layout table for location information
University of Bonn, Dept. of Psychiatry Recruiting
Bonn, Germany, D-53105
Contact: Dieter Schoepf, MD   
Principal Investigator: Dieter Schoepf, MD         
Sub-Investigator: Henrik Walter, MD, PhD         
University of Freiburg, Dept. of Psychiatry and Psychotherapy Recruiting
Freiburg, Germany, D-79104
Contact: Claus Normann, MD    +49-761-2706501   
Principal Investigator: Claus Normann, MD         
Sub-Investigator: Elisabeth Schramm, PhD         
Sponsors and Collaborators
University Hospital Freiburg
University Hospital, Bonn
Layout table for investigator information
Principal Investigator: Claus Normann, MD University of Freiburg, Dep. of Psychiatry
Principal Investigator: Dieter Schoepf, MD University of Bonn, Clinic for Psychiatry and Psychotherapy
Layout table for additonal information
Responsible Party: Dr. Claus Normann, University of Freiburg, Dep. of Psychiatry, Germany Identifier: NCT00837564    
Other Study ID Numbers: CBASP-1
First Posted: February 5, 2009    Key Record Dates
Last Update Posted: June 30, 2010
Last Verified: July 2010
Keywords provided by University Hospital Freiburg:
chronic depression
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs